Observational study of chikungunya vaccine effectiveness in Brazil
Treatments studied
Part of Infections clinical trials.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You live in a specific area in Brazil where a pilot vaccination program is running.
- You are in the age group allowed to receive the VLA1553 vaccine.
- You had symptoms that looked like chikungunya or dengue, and a blood test was taken within 5 days of those symptoms starting.
- Your doctor reported your case to the Brazilian health system (SINAN) and your blood sample was registered in GAL.
- Your health records (age, sex, where you live, date of symptom start, and where you were tested) are complete in the national databases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
This study looks at how well the chikungunya vaccine works in real life, how safe it is, and how the body's immune system responds. It is for adults who are eligible for the vaccine according to French health guidelines.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
This study looks for the chikungunya virus in semen. It may help understand if the virus can be passed through sex, and why it's important for men who have been infected.
This study tests how well the chikungunya vaccine (IXCHIQ) triggers an immune response in people aged 12 to 59. It is a phase 2 trial to see if the vaccine produces a good antibody response.
Hear when a new Chikungunya Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.